Skip to main content

Short-term in vitro assays for long-term toxicity

Objective

The development of new pharmaceutical compounds will be more efficient if human relevant toxicology information early in the selection process is available. While acute toxicity can be reasonably detected during the early preclinical stages of drug development, long-term toxicity is more difficult to predict, relying almost exclusively on animal experiments Animal experimentation of this kind is expensive and time consuming, raises ethical issues and do not necessarily represent a toxicological relevance to man. This project address the urgent need to develop in vitro based systems which are capable of predicting long term toxicity in humans. The major objectives of this project are:1)To develop advanced cell culture systems which as best possible represents the human liver and kidney in vivo. This will be achieved using combined strategies namely:co-cultures of resident cell types,targeted cell transformation,stem cell technology and new developments in organotypic cell culture (i.e. perfusion cultures and 3D cultures).2)To identify specific early mechanistic markers of toxin induced cell alterations by using integrated genomic,proteomic and cytomic analysis.3)To establish and prevalidate a screening platform (cell systems together with analysis tools) which is unambiguously predictive of toxin induced chronic renal and hepatic disease.This proposal is unique in it's mechanistic integration of the three levels of cellular dynamics (genome, proteome and cytome) together with advanced cell culture technology to detect early events of cellular injury. Only with such an integrated approach will in vitro techniques ever be applicable to predicting chronic toxicity in man. This project,if successful will(1) contribute to the replacement of animal testing in drug development, (2) increase t

Call for proposal

FP6-2002-LIFESCIHEALTH
See other projects for this call

Coordinator

FUNDACIÓN HOSPITAL UNIVERSITARIO "LA FE"
Address
Av Campanar N°21
Valencia
Spain

Participants (12)

INNSBRUCK MEDICAL UNIVERSITY, INSTITUTE OF PHYSIOLOGY
Austria
Address
Fritz-preglstrasse 3
Innsbruck
VRIJE UNIVERSITEIT BRUSSEL
Belgium
Address
Laarbeeklaan 103
Brussels
LEIDEN UNIVERSITY MEDICAL CENTRE
Netherlands
Address
Albinusdreef 2
Leiden
NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Ireland
Address
Belfield
Dublin 4
BAYER AG / BAYER HEALTH CARE
Germany
Address
Aprather Weg 18A
Wuppertal
NOVARTIS PHARMA AG
Switzerland
Address

Basel
PROGENIKA BIOPHARMA S.A.
Spain
Address
Ibaizabal Bidea, Parque Tecnologico, Edificio 801
Derio
PHARMAMAR S.A. SOCIEDAD UNIPERSONAL
Spain
Address
Poligono Industria La Mina, Avda. De Los Reyes, N°1
Colmenar Viejo - Madrid
JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, A DIVISION OF JANSSEN PHARMACEUTICA N.V.
Belgium
Address
Turnhoutseweg 30
Beerse
EUROPEAN CONSENSUS PLATFORM ON 3R-ALTERNATIVES
Belgium
Address
Paul Deschanel Laan 36-38
Brussels
JOINT RESEARCH CENTRE
Belgium
Address
Rue De La Loi, 200
Brussels
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
France
Address
Rue De Tolbiac
Paris